Justin Chivinski practices in the area of corporate law. Mr. Chivinski is a 2013 graduate of Duke University School of Law and a graduate of the Pennsylvania State University.
•Duke University School of Law, J.D., 2013
•The Pennsylvania State University, B.S., Finance, 2007
•Duane Morris LLP
- Associate, 2013-present
|Reported Cases||Representative Matters: Represented Vonage Holdings Corp. in its acquisition of gUnify, Inc., a cloud-based technology company whose middleware solution integrates the Company's cloud communications platform with widely used SaaS business applications, including Google for Work, Zendesk, Salesforce's Sales Cloud, Clio, and other CRM solutions. Represented a pain-focused pharmaceutical company in closing a $30 million venture loan. The lender is an investment firm dedicated to the healthcare sector. Represented Aclaris Therapeutics, Inc., a specialty pharmaceutical company with a focus on the development of novel topical dermatological therapies, in connection with the sale of $21.3 million of Series B Preferred Stock. Represented Current Analysis, Inc., an IT and telecom market-research firm, in the sale of the company to Progressive Digital Media Group through a merger transaction for a purchase price of $19.6 million. Represented BeachGlow: Concerts for Charity, Inc., a non-profit concert producer, in helping the organization incorporate, obtain tax exempt status and negotiate various contracts pertaining to a concert. Represented Ludwig Bohler in the sale of his interests in Bohler Engineering, P.C. and a series of affiliated entities to employees who collectively owned most of the interests in the acquired entities not previously owned directly or indirectly by Mr. Bohler. Represented Iroko Pharmaceuticals, a global specialty pharmaceutical company dedicated to advancing the science of responsible pain management, in securing $75 million in debt financing to support general business operations and the commercialization of Iroko's FDA-approved ZORVOLEX (diclofenac), a drug that uses iCeutica Inc.'s proprietary SoluMatrix Fine Particle Technology to both reduce the dosage of active ingredients ingested by the patient and accelerate the dissolution of the drug in the patient. Represented Alexar Therapeutics, Inc., a newly formed derm-focused pharmaceutical company, in connection with the sale of $21.5 million of Series A-1 and Series A-2 Preferred Stock to Third Point, New Science Ventures and Palo Alto, venture capital firms active in the pharmaceutical space, and the simultaneous closing of the purchase of the stock of Anayaderm, a development-stage pharmaceutical company. Represented a French media and sports management company in connection with the acquisition by its U.S. subsidiary of a golf events management company.|